Wegovy vs Mounjaro: Which Weight Management Treatment?
Understanding 7.5mg Mounjaro to Wegovy: Mechanism Differences
When considering switching from 7.5mg Mounjaro to Wegovy, understanding the fundamental mechanism differences is crucial. Mounjaro (tirzepatide) works as a dual agonist targeting both GIP and GLP-1 receptors, whilst Wegovy (semaglutide) specifically targets GLP-1 receptors only. This single-pathway approach for Wegovy may offer different appetite suppression patterns compared to Mounjaro's dual-hormone mechanism. Both prescription-only medicines work alongside a reduced-calorie diet and increased physical activity to support weight management goals.
The transition from 7.5mg Mounjaro to Wegovy requires careful consideration of dosing equivalencies and individual response patterns. Mounjaro's 7.5mg dose represents a mid-range maintenance level in its dosing schedule, whilst Wegovy's maximum maintenance dose is 2.4mg weekly. These numerical differences reflect the distinct potency profiles rather than indicating superiority of either treatment. Your prescriber can determine the appropriate starting dose when transitioning between these GLP-1-based therapies.
7.5mg Mounjaro to Wegovy: UK Pricing and Value Comparison
EverydayMeds offers transparent pricing for both treatments, with Wegovy starting at £79.99 for the 0.25mg starter dose using code FIRST40 for new customers. The complete Wegovy dose escalation includes 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. Returning customers benefit from code DOSE25 applied at checkout. Bundle options like the Intro Trio (0.25mg, 0.5mg, 1mg) provide three months of treatment for £299.99, offering convenience and Reliable Supply continuity.
When comparing 7.5mg Mounjaro to Wegovy costs, consider the different dose escalation schedules and maintenance requirements. Both treatments require prescription-only medicine status through our GPhC-registered pharmacy (#9012878), with identical clinical assessment and prescriber review processes. The 3-minute online assessment standard review takes 3 working days, or express 24-hour service is available. Next-day cold-chain delivery ensures both treatments arrive in optimal condition regardless of your choice.
Clinical Evidence: 7.5mg Mounjaro to Wegovy Treatment Outcomes
Wegovy's clinical evidence comes primarily from the STEP trial programme, with STEP 1 showing approximately 15% average weight loss at 68 weeks versus 2.4% with placebo when used alongside diet and exercise modifications. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events (HR 0.80) in patients taking Wegovy. These results establish Wegovy's efficacy profile for weight management in eligible adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities.
While both treatments have robust clinical evidence, direct head-to-head comparisons between 7.5mg Mounjaro and Wegovy aren't available due to different trial designs and populations. The evidence for each treatment comes from separate clinical programmes with distinct primary endpoints and methodologies. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment profile aligns best with your individual circumstances and medical history.
How Wegovy Works: 7.5mg Mounjaro to Wegovy Mechanism
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates blood sugar and appetite control. This mechanism promotes feelings of satiety after smaller meals and may reduce food cravings by acting on brain appetite centres. Unlike Mounjaro's dual-receptor approach, Wegovy's focused GLP-1 pathway provides targeted appetite suppression through a single, well-characterised mechanism. The once-weekly injection via FlexTouch pre-filled pen delivers consistent semaglutide levels throughout the week. When considering 7.5mg Mounjaro to Wegovy, this simplified mechanism may offer more predictable appetite effects for some patients. The treatment works alongside lifestyle modifications including reduced-calorie diet and increased physical activity as part of a comprehensive weight management approach.
7.5mg Mounjaro to Wegovy: Ordering Process at EverydayMeds
Accessing both Wegovy and Mounjaro through EverydayMeds follows an identical streamlined process designed for UK patients. The 3-minute online clinical assessment covers medical history, current medications, weight management goals, and contraindication screening for either treatment option. Following assessment submission, qualified prescribers review applications within standard 3 working days or express 24-hour service. Once approved, next-day delivery via temperature-controlled cold-chain ensures your chosen treatment arrives in optimal condition. Both treatments require prescription-only medicine status, and our GPhC-registered pharmacy service (#9012878) maintains full regulatory compliance. Whether choosing 7.5mg Mounjaro equivalent dosing or transitioning to Wegovy's different schedule, the ordering process remains consistent and straightforward.
Storage and Practical Considerations: 7.5mg Mounjaro to Wegovy
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable at room temperature for up to 6 weeks once removed from refrigeration versus Mounjaro's 21-day limit. Both treatments require initial refrigerated storage at 2-8°C, but Wegovy's extended room temperature stability provides significant practical advantages for travel or daily use. The FlexTouch pen design delivers precise dosing with clear dose escalation from 0.25mg through to 2.4mg maintenance dosing. When transitioning from 7.5mg Mounjaro to Wegovy, patients benefit from simplified once-weekly injection scheduling and reduced storage concerns. The dose escalation schedule cannot be accelerated, ensuring optimal tolerance as your body adjusts to this prescription-only medicine. Both treatments require proper disposal of used pens through appropriate pharmaceutical waste channels.
7.5mg Mounjaro to Wegovy: Treatment Transition Considerations
Patients considering the switch from 7.5mg Mounjaro to Wegovy should understand there's no direct dose conversion between these different medications. Wegovy initiation typically begins with the 0.25mg starter dose regardless of previous Mounjaro dosing, allowing proper tolerance assessment for the semaglutide-based mechanism. Your prescriber will determine appropriate washout periods and monitoring requirements when transitioning between these treatments. The change from dual-hormone targeting to single GLP-1 pathway may result in different appetite suppression patterns or side effect profiles.
EverydayMeds supports patients throughout treatment transitions with comprehensive prescriber guidance and flexible ordering options. Both treatments remain available through our platform, ensuring continuity of care regardless of treatment changes. The clinical team provides ongoing support for patients switching from 7.5mg Mounjaro to Wegovy, monitoring tolerance and efficacy throughout the transition period. This personalised approach ensures optimal outcomes when changing between these prescription-only weight management therapies.
Complete Your 7.5mg Mounjaro to Wegovy Assessment Today
Ready to explore whether Wegovy suits your weight management goals better than your current treatment? EverydayMeds provides access to both options through our comprehensive clinical assessment platform. New customers receive discount code FIRST40 at checkout, with returning customers using DOSE25 for continued savings. Our qualified prescribers review every application individually, ensuring appropriate treatment selection whether you're continuing with Mounjaro or transitioning to Wegovy's focused GLP-1 approach. Both treatments require prescription-only medicine status and work alongside diet and exercise modifications for optimal results. Visit our weight loss collection to begin your clinical assessment and take the next step in your weight management journey with expert prescriber guidance from our GPhC-registered team.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
